ArticleCASPubMedGoogle Scholar Chia, S. et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.J. Clin. Oncol.26, 5697–5704 (2008). ArticleCASPubMedGoogle Scholar Payne, S. J., Bowen, R. L...
Additionally, there are tools that estimate life-limiting toxicity risk from chemotherapy and life expectancy, which are both important issues in the risk鈥揵enefit discussion. For very low-risk cancers, such as non-invasive and small lymph node (LN)-negative cancers, the benefits of any ...
inoperable or metastatic HR-positive, HER2-negative breast cancer, progressed on or are not eligible for endocrine therapy, have an ECOG performance status of 0 or 1, at least 1 measurable lesion, adequate organ and bone marrow function, and a minimum life expectancy of 12 wee...
The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor-positive, HER2-negative breast cancer were treated with datopotamab deruxtecan.
The international, prospective, open-label, randomized trial was launched to evaluate the safety and efficacy of the SERD in patients with ER-positive, HER2-negative metastatic or locally advanced breast cancer that was progressing on 6 or more months of continuous endocrine therapy.2,3...
简要标题 Sacituzumab Govitecan in Primary HER2-negative Breast Cancer 临床分期 Phase 3 招募状态 Active, not recruiting 首次公开日期 2020-10-20 条件/疾病 Triple Negative Breast Cancer | HER2-negative Breast Cancer 干预/治疗 Sacituzumab govitecan | Capecitabine | Carboplatin | Cisplatin 申办方 Germa...
Patients with measurable first-line HER2/neu—negative MBC were eligible. This trial began as a 2-arm study with a docetaxel-alone arm. When bevacizumab became widely available, it was converted to a 1-arm open-label trial of docetaxel/bevacizumab. Patients enrolled in the docetaxel-alone arm...
Inpatient Hematology/Oncology, leader, Breast Cancer Clinical Research, GW Cancer Center, discusses the potential clinical significance of the ongoing phase 2/3 AIPAC-003 trial (NCT05747794) investigating eftilagimod alpha in combination with paclitaxel in patients with HER2-negative and...
Women with childbearing potential must have a negative pregnancy test at screening; also excluded are women with childbearing potential, including women whose last menstrual period was <1 year before screening, unable or unwilling to use adequate contraception from study start to 1 year after ...
The p53-positive patients were more likely to achieve tpCR and bpCR than p53-negative patients (P < 0.05). The incidence of hypokalemia and diarrhea in the case group was higher than that in the control group (P < 0.05). The AEs developed were all manageable, and no treatment...